

IPAC Member Survey on United Kingdom Manufacture and Export of HFC MDIs – Sharing Insights

IPAC HFC MDI Survey – Background and Methods


In 1Q 2023, the International Pharmaceutical Aerosol Consortium (IPAC) conducted a survey of its member companies regarding the manufacture of HFC MDIs in the United Kingdom, including volumes imported and exported. In light of commercial sensitivities and to respect competition laws, the IPAC Secretariat collected the data from individual companies and held it in strict confidence. This document summarises the compiled, aggregate survey responses. All data refers to calendar year 2022. These companies represent a significant portion of the UK market for MDIs. We hope this data is helpful for UK policymakers.

The survey includes data from the following companies:

- AstraZeneca
- Chiesi Farmaceutici
- GSK
- Kindeva Drug Delivery
- Teva
- Organon
- Recipharm

Overview

The UK is a global manufacturer of medical inhalers and revising the F-Gas regulation has bearing on the supply of these life-saving medicines to regions beyond the UK. As detailed below, the survey shows that approximately **89% of MDIs manufactured in the UK were exported**.




55,032,000
MDIs IMPORTED
into the UK





29,665,651
MDIs MANUFACTURED
in the UK




26,519,689
MDIs EXPORTED
from the UK

Total MDIs in UK: **58,177,962***

Details on the 26,519,689 MDIs Exported from the UK



About IPAC

IPAC's mission is to ensure that environmental policies relevant to inhaled therapies are patient-centric and appropriately balance both patient care and sustainability objectives. For details, see: www.ipacinhaler.org.

Please contact the IPAC Secretariat, Maureen Hardwick, with any questions at info@ipacinhaler.org or +13019807837.

* This figure represents the respondents' total quantity of MDIs manufactured in the UK minus net exports.